Navigation Links
DOR BioPharma Announces NIH Grant Award to Support Phase 1/2 Clinical Trial of DOR201 in Radiation Enteritis
Date:9/8/2009

PRINCETON, N.J., Sept. 8 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc. (OTC Bulletin Board: DORB) (DOR or the Company), a late-stage biotechnology company, announced today that the National Institutes of Health (NIH) has awarded DOR a Small Business Innovation Research (SBIR) grant to support the conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP), for the prevention of acute radiation enteritis. The award will provide DOR with approximately $500,000 over a two-year period.

The grant application included the Phase 1/2 protocol BDP-ENT-01, which is designed as a multicenter, open-label, sequential, dose-escalation study in approximately 36 patients. Patients with rectal cancer who are scheduled to undergo concurrent radiation and chemotherapy prior to surgery will be enrolled in four dose groups. The objectives of the study are to evaluate the safety and maximal tolerated dose of escalating doses of DOR201, as well as the preliminary efficacy of DOR201 for prevention of signs and symptoms of acute radiation enteritis. The study is expected to be initiated in 2009.

Acute radiation enteritis is caused by radiation-induced death of cells in the lining of the bowel. As bowel cells die and are not replaced, gastrointestinal toxicity develops over the next few days and weeks due to an inflammatory response to dead cells and bacteria, with chronic diarrhea, vomiting and pain being the major symptoms. The addition of chemotherapy often exacerbates the onset, severity and debilitation related to intestinal symptoms. Radiation enteritis often results in delay or interruption of the cancer treatment. There are over 100,000 patients annually in the United States who receive abdominal or pelvic external beam radiation treatment for cancer, and these patients are at risk of developing acute and chronic radiation enteritis.

"Radi
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Research-Based Biopharmaceutical Company Awards Trials to DATATRAK
2. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
3. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
4. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
5. CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders
6. DOR BioPharma Receives EMEA Agreement on the Design of its Confirmatory Phase 3 Clinical Trial of orBec(R) in GI GVHD
7. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
10. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
11. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 22, 2015  China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based ... the resignation of Mr. Fuxiang Zhang as ... immediately. Ms. Rebecca Yingnan Zhang has been ... of directors, effective immediately. Meanwhile, Ms. Zhang resigned from ...
(Date:5/21/2015)... Research and Markets ... of the "Arthroscopy Devices Markets Worldwide" ... http://photos.prnewswire.com/prnh/20130307/600769) , ,The purpose of this report ... market for Arthroscopy Devices. The report discusses ... market for these products. , ,Product - ...
(Date:5/21/2015)... , 21. Mai 2015 ... ), ein Unternehmen für Arzneimittel im ... Entwicklung und Vermarktung von Locilex® (Pexiganan-Creme ... heute eine wissenschaftliche Posterpräsentation an, welche ... Unternehmens vorstellt, OneStep-1 und OneStep-2, in ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 3Analysing Arthroscopy Devices Markets Worldwide 2014-2020 2Analysing Arthroscopy Devices Markets Worldwide 2014-2020 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 2Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 3Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 4Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 5Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 6Dipexium kündigt eine Präsentation auf dem 7. International Symposium on the Diabetic Foot an 7
... 2011 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) ... BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in development ... inihibtors have been validated to show survival benefits in cancer ... in combination with DNA damaging agents, and BMN 673 appears ...
... 2011 Virtual Radiologic (vRad), a technology-enabled national radiology ... the Teleradiology Services market segment by independent research and ... customer surveys and interviews conducted by KLAS and is ... in KLAS Awards: Software & Professional Services report. ...
Cached Medicine Technology:BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 2BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers 3Virtual Radiologic Ranked #1 for Teleradiology Services for Third Consecutive Year 2
(Date:5/23/2015)... With the implementation of the Affordable ... increasingly difficult to provide their employees with a viable ... insurance for employees stand to face strict penalties. Never ... part of a business’s success or failure. In an ... USA Doctors has created a varying level of less ...
(Date:5/23/2015)... Javon Bea Mercy Health System CEO ... Center, 557 N. Washington St., Janesville, will host an ... pm. , The 8-week clinic is lead by Brent ... who will offer training that encompasses a warm-up, training ... show selection and weekly training plans. , The program ...
(Date:5/22/2015)... 22, 2015 The American College of ... in June. They will hold a webinar on the ... two-day class on Classical Chinese Medicine. , Webinar – ... Steve Given, the Dean of Clinical Education, will lead ... First Professional Doctorate program. ACTCM is currently developing this ...
(Date:5/22/2015)... Omar Ahmad Barrada, a junior at Milton ... 2015 Congress of Future Medical Leaders in Boston, Mass. ... “America’s highest achieving high school students.” , “I’m excited ... goals and learn better study habits,” said Omar. “The ... we can ask the surgeons questions.” , The goal ...
(Date:5/22/2015)... Carnegie Science Center and ... new partnership to develop BodyTech, a dynamic, three-pronged health ... includes a new exhibit at the Science Center called ... a new traveling science show, Anatomy Adventure, which will ... , Designed to explore a wide range of topics ...
Breaking Medicine News(10 mins):Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:ACTCM Announces Upcoming June Events 2Health News:Milton Hershey School Student Chosen for Congress of Future Medical Leaders 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 2Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 3Health News:Carnegie Science Center, Allegheny Health Network Partner to Create BodyTech 4
... Provides Update on Oncology Pipeline Progress, SAN DIEGO, ... announced financial results for the three and nine,months ended ... 30,2007, the Company posted revenues of $7.6 million and ... ended September 30, 2007, revenues were $27.1,million and the ...
... Human Vaccine Against West Nile Virus Today; ... Disease Endemic in the United States, ... of sanofi-aventis Group, announced today that it has,signed an exclusive ... of a West Nile vaccine to help fight against,this serious, ...
... urinary levels of certain molecules might have the potential ... ailment caused by the autoimmune disease lupus, UT Southwestern ... a quartet of molecules may have potential diagnostic significance, ... senior author of a study available online at the ...
... CRME TSX: COM, VANCOUVER, Nov. 12 /PRNewswire-FirstCall/ - ... that it will report 2007 third,quarter financial results on ... a teleconference call and webcast at 4:30pm Eastern Time,(1:30pm ... To access the conference call, please dial 416-340-8010 ...
... Nov. 12 ,Seeking to expand Indo-U.S. healthcare ... Healthy India launched its inaugural,executive mission to ... from the,most prominent players in healthcare, including: ... Avesthagen, Excel Life Sciences,Cognizant, Stryker, BD, Yes ...
... plaguing inner-city youth at epidemic rates, the report of ... Journal of the American College of Surgeons illustrated a ... study showed that Caught in the Crossfire, a hospital-based ... system among youth aged 12 to 20. Additionally, ...
Cached Medicine News:Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 2Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 3Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 4Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 5Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 6Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 7Health News:SGX Pharmaceuticals Announces Financial Results for the Three and Nine Months Ended September 30, 2007 8Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 2Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 3Health News:Sanofi Pasteur and Acambis Join Forces to Bring West Nile Vaccine to Market 4Health News:Researchers investigate ways to detect lupus-associated kidney disease 2Health News:Cardiome To Release Third Quarter Results 2Health News:Cardiome To Release Third Quarter Results 3Health News:USIBC Launches Healthcare Mission to India 2Health News:Study quantifies cost-benefit of hospital-based program to keep youth out of prison 2Health News:Study quantifies cost-benefit of hospital-based program to keep youth out of prison 3
Meyerding Laminectomy Retractors, self-retaining....
Scoville-Haverfield Hemilaminectomy Retractor...
Bookwalter Spinal Retractor...
Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region....
Medicine Products: